Skip to main content

Table 3 Dose schedule

From: Amantadine for NeuroenhaNcement in acutE patients Study - a protocol for a prospective pilot proof of concept phase IIb study in intensive and intermediate care unit patients (ANNES)

 

Morning

10.00 am

Noon

1.00 p.m.

Evening

Night

note

Day 1

100 mg

100 mg

0

0

 

Day 2

100 mg

100 mg

0

0

 

Day 3

100–200 mg

100–200 mg

0

0

Dose can be doubled in case of unresponsiveness to drug; minimum duration of treatment

 

200 mg

200 mg

0

0

In case of non-responder

Day 4

100 mg

100 mg

0

0

 
 

200 mg

200 mg

0

0

In case of non-responder

Day 5

100 mg

100 mg

0

0

Maximum duration of treatment

 

200 mg

200 mg

0

0

In case of non-responder

Maximum duration of treatment